<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850031</url>
  </required_header>
  <id_info>
    <org_study_id>ACU-P08-020A</org_study_id>
    <nct_id>NCT00850031</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes</brief_title>
  <acronym>ACI</acronym>
  <official_title>A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay (ACI)™ ACI 7000PDT in Presbyopic Subjects (OUS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcuFocus, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcuFocus, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will&#xD;
      provide an effective method for the correction of presbyopia in patients who have normal&#xD;
      distance vision but need a correction such as glasses or contact lenses to see clearly at&#xD;
      near.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The loss of near vision and the ability to perform tasks that require near vision is part of&#xD;
      the normal aging process. This natural transformation in the eye occurs as a result of the&#xD;
      loss of accommodation of the crystalline lens, a condition known as presbyopia. The&#xD;
      crystalline lens is responsible for the accommodative properties of the human eye, as&#xD;
      established by Young in 1801, over 200 years ago.1 During accommodation, the ciliary muscle&#xD;
      contracts, decreasing tension on the zonules, and allowing the crystalline lens to thicken,&#xD;
      increasing its refractive power. This mechanism of accommodation and thickening of the lens&#xD;
      provides the eye with adequate refractive power for near vision. The loss of accommodation&#xD;
      with aging is the result of changes in the crystalline lens composition that prevent the&#xD;
      natural accommodative process from occurring. This is associated with the gradual loss of&#xD;
      near vision without external correction, generally in the form of spectacles.&#xD;
&#xD;
      The AcuFocus™ ACI 7000PDT represents new technology based on the well-established concept of&#xD;
      small-aperture optics. In early cameras, depth of focus was controlled by reducing the&#xD;
      aperture through which light enters. The smaller the aperture, the greater the depth of focus&#xD;
      will be. This concept also applies to the human eye. In the eye of a presbyopic emmetrope,&#xD;
      the lens cannot accommodate sufficiently to focus the light rays from a near object onto a&#xD;
      single point on the retina. Thus, a point object is imaged as a blur circle on the retina,&#xD;
      and images of extended objects are degraded as well. If an opaque disc with a small aperture&#xD;
      in the center is placed in front of the eye, the peripheral rays will be obscured while the&#xD;
      central rays pass unaffected. Since peripheral rays enter the eye at a larger angle, they&#xD;
      create a larger blur circle at the retinal image plane. Eliminating these peripheral rays&#xD;
      reduces the size of the blur circle, improving image resolution.&#xD;
&#xD;
      In presbyopic subjects, objects closer than arm's length are focused behind the retina, thus&#xD;
      creating blurred retinal images (which are composed of blur circles). A small aperture inlay&#xD;
      placed in front of the eye of these subjects allows them to see at near by reducing the size&#xD;
      of the blur circle.&#xD;
&#xD;
      AcuFocus, Inc. has developed a stationary intracorneal inlay designed to create a small&#xD;
      aperture effect. The implant is intended to be placed intra-stromally either under a corneal&#xD;
      flap or into a corneal pocket. Placement of the ACI will be centered over the pupil in the&#xD;
      non-dominant eye. The ACI is expected to increase the depth of focus of the eye by reducing&#xD;
      the circle of blur. Based on theoretical calculations of small aperture optics, the ACI is&#xD;
      expected to provide presbyopic subjects with improvement of near and intermediate vision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Uncorrected Near Visual Acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of subjects who achieved UCNVA of 20/40 or better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Near Uncorrected Visual Acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Mean subjective rating via questionnaire on 1 to 7 rating scale (1= very dissatisfied and 7 = very satisfied).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>AcuFocus Corneal Inlay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcuFocus Corneal Inlay</intervention_name>
    <description>Inlay implanted in cornea for improvement of near vision</description>
    <arm_group_label>AcuFocus Corneal Inlay</arm_group_label>
    <other_name>AcuFocus Corneal Inlay ACI 7000 PDT</other_name>
    <other_name>AcuFocus KAMRA inlay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be natural emmetropes needing a minimum magnitude of +1.00D to +2.50D of&#xD;
             reading add.&#xD;
&#xD;
          2. Subjects must have uncorrected near visual acuity worse than 20/40 and better than&#xD;
             20/100 in the eye to be implanted.&#xD;
&#xD;
          3. Subject must have distance visual acuity correctable to at least 20/20 in both eyes.&#xD;
&#xD;
          4. Subjects must have a preoperative spherical equivalent of plano defined as +0.50D to&#xD;
             -0.75D with no more than 0.75D of refractive cylinder as determined by cycloplegic&#xD;
             refraction in the eye to be implanted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a difference of &gt; 1.00D between the spherical equivalent manifest&#xD;
             refraction and the spherical equivalent cycloplegic refraction.&#xD;
&#xD;
          2. Subjects with anterior segment pathology, including cataracts, in the eye to be&#xD;
             implanted.&#xD;
&#xD;
          3. Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease, or&#xD;
             any corneal abnormalities (including endothelial dystrophy, guttata, recurrent corneal&#xD;
             erosion, etc.) in the eye to be implanted.&#xD;
&#xD;
          4. Subjects with ophthalmoscopic signs of keratoconus (or keratoconus suspect) in the eye&#xD;
             to be implanted.&#xD;
&#xD;
          5. Subjects with a history of chronic dry eye not responding to therapy.&#xD;
&#xD;
          6. Subjects with distorted or unclear corneal mires on topography maps of the eye to be&#xD;
             implanted.&#xD;
&#xD;
          7. Subjects who require canthotomy to generate a corneal flap in the eye to be implanted.&#xD;
&#xD;
          8. Subjects with macular degeneration, retinal detachment, or any other fundus pathology&#xD;
             that would prevent an acceptable visual outcome in the eye to be implanted.&#xD;
&#xD;
          9. Subjects who have undergone previous intraocular or corneal surgery including cataract&#xD;
             and LASIK surgery.&#xD;
&#xD;
         10. Subjects with a history of herpes zoster or herpes simplex keratitis.&#xD;
&#xD;
         11. Subjects who have a history of steroid-responsive rise in intraocular pressure,&#xD;
             preoperative IOP &gt; 21 mmHg, glaucoma, or is a glaucoma suspect.&#xD;
&#xD;
         12. Subjects with a history of diagnosed diabetes, autoimmune disease, connective tissue&#xD;
             disease, or clinically significant atopic syndrome.&#xD;
&#xD;
         13. Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that&#xD;
             may affect wound healing, and any immunocompromised subjects.&#xD;
&#xD;
         14. Subjects who are using ophthalmic medication(s) other than artificial tears for&#xD;
             treatment of any ocular pathology including ocular allergy.&#xD;
&#xD;
         15. Subjects using systemic medications with significant ocular side effects.&#xD;
&#xD;
         16. Subjects who are pregnant, lactating, or of child-bearing potential and not practicing&#xD;
             a medically approved method of birth control.&#xD;
&#xD;
         17. Subjects with known sensitivity to planned study concomitant medications.&#xD;
&#xD;
         18. Subjects who are participating in any other ophthalmic drug or device clinical trial&#xD;
             during the time of this clinical investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perry Binder, MD</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Vista Laser Eye Clinics</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3185</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Institute</name>
      <address>
        <city>Bondi Junction</city>
        <zip>2022</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medizinische Privat-Universität, PMU, Universitätsklinikum</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats-Augenklinik, Department of Ophthalmology</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fendalton Eye Clinic</name>
      <address>
        <city>Fendalton</city>
        <state>Christchurch</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Eye</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore National Eye Centre</name>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optical Express</name>
      <address>
        <city>London</city>
        <zip>W1G 9AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.acufocus.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <results_first_submitted>July 20, 2016</results_first_submitted>
  <results_first_submitted_qc>December 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2017</results_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Presbyopia</keyword>
  <keyword>Accommodation</keyword>
  <keyword>Near visual acuity</keyword>
  <keyword>LASIK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>119 participants were consented for the study (enrolled), and 118 subsequently were implanted with the device (started) for the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AcuFocus Corneal Inlay</title>
          <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.&#xD;
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients between 45 and 60 years of age with presbyopia</population>
      <group_list>
        <group group_id="B1">
          <title>AcuFocus Corneal Inlay</title>
          <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.&#xD;
AcuFocus Corneal Inlay ACI 7000PDT: Inlay implanted in cornea for improvement of near vision</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Uncorrected Near Visual Acuity</title>
        <description>Percent of subjects who achieved UCNVA of 20/40 or better.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AcuFocus Corneal Inlay</title>
            <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.&#xD;
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Uncorrected Near Visual Acuity</title>
          <description>Percent of subjects who achieved UCNVA of 20/40 or better.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Near Uncorrected Visual Acuity</title>
        <description>Mean subjective rating via questionnaire on 1 to 7 rating scale (1= very dissatisfied and 7 = very satisfied).</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AcuFocus Corneal Inlay</title>
            <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.&#xD;
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Near Uncorrected Visual Acuity</title>
          <description>Mean subjective rating via questionnaire on 1 to 7 rating scale (1= very dissatisfied and 7 = very satisfied).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months, 6 months, 1 year, 2 years,3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AcuFocus Corneal Inlay</title>
          <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.&#xD;
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Stromal thinning secondary to abnormal healing response to corneal trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to bike accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization secondary to prostatectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hip replacement surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial punctate keratitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Vision</sub_title>
                <description>Decrease in BCDVA greater than 2 lines month 3 and later</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cornea</sub_title>
                <description>Corneal edema</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Intraocular Pressure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Limbal foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Corneal abrasion/erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Foreign bodies over inlay with anterior corneal surface defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Lens</sub_title>
                <description>Cataract</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Meibomian Gland Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Partial sidecut at inner edge of mask</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Conjunctival Cyst</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Upper eyelid chalazion</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Admission to hospital for severe headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Increased blood sugar</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Chest Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Non-insulin-dependent diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Benign Prostate Hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Flap complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Secondary Surgical Intervention</sub_title>
                <description>Inlay recentration</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Secondary Surgical Intervention</sub_title>
                <description>Epithelial ingrowth removal</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Knee injury &amp; surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eugenia Thomas, Director Clinical Trials</name_or_title>
      <organization>AcuFocus, Inc</organization>
      <phone>949/585-9511 ext 129</phone>
      <email>nthomas@acufocus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

